Holen Sie sich die Stockscreener-App
59.98
9.87%
-6.57
Schlusskurs vom Vortag:
$66.55
Offen:
$63.99
24-Stunden-Volumen:
759.89K
Relative Volume:
0.91
Marktkapitalisierung:
$2.57B
Einnahmen:
$147.17M
Nettoeinkommen (Verlust:
$-408.35M
KGV:
-5.3656
EPS:
-11.1787
Netto-Cashflow:
$-299.92M
1W Leistung:
-16.32%
1M Leistung:
+10.26%
6M Leistung:
-40.60%
1J Leistung:
+51.89%
1-Tages-Spanne:
$59.66
$65.53
1-Wochen-Bereich:
$54.52
$68.93
52-Wochen-Spanne:
$29.95
$118.84
Grail Inc Stock (GRAL) Company Profile
Firmenname
Grail Inc
Sektor
Branche
Telefon
(833) 694-2553
Adresse
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
59.98 | 2.86B | 147.17M | -408.35M | -299.92M | -11.18 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Mizuho | Neutral |
| 2026-03-18 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-19 | Eingeleitet | TD Cowen | Hold |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-11-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-10-17 | Eingeleitet | Guggenheim | Neutral |
Alle ansehen
Grail Inc Aktie (GRAL) Neueste Nachrichten
SHAREHOLDER CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Deadline on August 4, 2026 - 巴士的報
Levi & Korsinsky files GRAIL class action, sets August 4 deadline - scanx.trade
Grail, Inc. chief growth officer sells $91,070 in common stock By Investing.com - Investing.com Canada
Grail, Inc. chief growth officer sells $91,070 in common stock - Investing.com
[Form 4] GRAIL, Inc. Insider Trading Activity - Stock Titan
Grail Hit With Shareholder Suit Over Cancer Screening Trial - Bloomberg Law News
Grail investors face August 4, 2026 deadline for securities class action over failed cancer trial results. - Pluang
Grail faces class action lawsuit after failing primary endpoint in cancer detection trial, stock drops 50%. - Pluang
Investor Notice: Robbins LLP Informs Investors of the Grail, Inc. Class Action Lawsuit - The AI Journal
GRAL INVESTOR ALERT: GRAIL, Inc. Investors with Substantial - GlobeNewswire
GRAL INVESTOR ALERT: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead the Grail Class Action Lawsuit – RGRD Law - GlobeNewswire Inc.
GRAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Grail - GlobeNewswire
GRAL Initiated Coverage by Goldman Sachs -- Rating Set to Neutra - GuruFocus
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of GRAIL, Inc. Common Stock and Sets a Lead Plaintiff Deadline of August 4, 2026 - GlobeNewswire
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
Goldman Sachs Initiates Coverage on GRAIL With Neutral Rating, $60 Price Target - Moomoo
Here's Why Grail Stock Soared Higher in May (And Where the Company is Heading Now) - Yahoo Finance
Grail stock initiated at Neutral by Goldman Sachs on FDA uncertainty By Investing.com - Investing.com South Africa
Grail stock initiated at Neutral by Goldman Sachs on FDA uncertainty - Investing.com India
GRAIL, Inc. Stock Hits Day Low of $54.83 Amid Price Pressure - Markets Mojo
Grail Stock Surges Over 11 Percent Following Mixed Cancer Test Presentation - asatunews.co.id
Why Grail Stock Popped Today - Yahoo Finance
Grail Stock Plummeted After Galleri Cancer Test NHS Trial Failed - asatunews.co.id
Is Grail Stock a Bad-News Buy After Its Recent Pullback? - Yahoo Finance
Why Grail Shares Are Suddenly Racing Higher - TipRanks
Form 144 GRAIL For: 3 June By Investing.com - Investing.com India
CEO Ofman granted 31K RSUs in GRAIL (NASDAQ: GRAL) equity awards - Stock Titan
GRAL (NASDAQ: GRAL) proposed sale of 2,914 vested RSU shares reported - Stock Titan
GRAIL, Inc. (GRAL) Shareholder/Analyst CallSlideshow (NASDAQ:GRAL) 2026-06-03 - Seeking Alpha
GRAIL's Galleri test cuts stage 4 cancer diagnoses in study despite missed endpoint - MSN
GRAIL (NASDAQ: GRAL) officer reports initial ownership of 165,229 shares - Stock Titan
A Look At GRAIL (GRAL) Valuation After A Sharp One Day Share Price Drop - Yahoo Finance
GRAIL Names Joshua Ofman CEO, Enhances Leadership Compensation - The Globe and Mail
At ASCO, Grail points to positive signals in MCED data - MedTech Dive
Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL) - The Globe and Mail
GRAIL’s Galleri Cleared Secondary Bars At ASCO, But Primary Endpoint Miss Remains - Citeline News & Insights
GRAL News | GRAIL INC (NASDAQ:GRAL) - ChartMill
Wolfe Research initiates Grail stock coverage with Peerperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates Grail stock coverage with Peerperform rating - Investing.com
Why Grail shares crashed today - MSN
Galleri trial data and new CEO package at GRAIL (NASDAQ: GRAL) spotlight MCED progress - Stock Titan
Grail (GRAL) Sees Significant Drop of 18.4% - GuruFocus
Why Grail Shares Crashed Today - The Motley Fool
GRAIL, Inc. (GRAL): One of the Best Stock Picks of Jeff Bezos - Insider Monkey
GRAIL (GRAL) Is Up 6.7% After Mixed Galleri Trial Data At ASCO 2026Has The Bull Case Changed? - Yahoo Finance
Grail (GRAL) Sees Significant Decline in Stock Price - GuruFocus
ASCO 2026: Grail shifts focus to secondary endpoints in UK study - BioWorld News
Grail stock tumbles 20% on mixed PATHFINDER 2 trial results - Investing.com
GRAIL Shares Fall Pre-Bell After Galleri Trial Misses Primary Endpoint - Moomoo
Grail stock tumbles 20% on mixed PATHFINDER 2 trial results By Investing.com - Investing.com Australia
GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint - inkl
Finanzdaten der Grail Inc-Aktie (GRAL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):